arrow
返回

DC programming and DCA for sparse optimal scoring problem

delete2016-04-01
delete15
PRE
AI
H
Hoai An Le Thi *
D
Duy Nhat Phan
DOI:10.1016/j.neucom.2015.12.068delete
delete原文链接
delete原文求助
delete分享
delete收藏
摘要

摘要

En 中文
Linear Discriminant Analysis (LDA) is a standard tool for classification and dimension reduction in many applications. However, the problem of high dimension is still a great challenge for the classical LDA. In this paper we consider the supervised pattern classification in the high dimensional setting, in which the number of features is much larger than the number of observations and present a novel approach to the sparse optimal scoring problem using the zero-norm. The difficulty in treating the zero-norm is overcome by using appropriate continuous approximations such that the resulting problems are solved by alternating schemes based on DC (Difference of Convex functions) programming and DCA (DC Algorithms). The experimental results on both simulated and real datasets show the efficiency of the proposed algorithms compared to the five state-of-the-art methods. (C) 2016 Elsevier B.V. All rights reserved.
Keyword:
Feature selection
Linear discriminant analysis
Optimal scoring
DC programming
DCA
Alternating scheme
AI总结

AI总结

对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Neurocomputing 封面图
Neurocomputing
IF:
6.5
论文数:
2.5W
被引数:
6.5W

机构

U
universite de lorraine
学者数:
1.8W
论文数: 1.4W
被引数: 27
T
Ton Duc Thang University
学者数:
3.4K
论文数: 4.8K
被引数: 6.6K
引用论文

引用论文

Developing the future of gamma-ray astrophysics with monolithic silicon pixels
err2021-12-01
err0
errOAAI
errIsabella Brewer; Michela Negro; Nicolas Striebig; Carolyn Kierans; Regina Caputo; Richard Leys; Ivan Peric; Henrike Fleischhack; Jessica Metcalfe; Jeremy Perkins
err分享
err收藏
DC approximation approaches for sparse optimization
err2015-07-01
err152
errOAAI
errLe Thi, H. A.; Dinh, T. Pham; Le, H. M.; Vo, X. T.
err分享
err收藏
Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.
err2021-05-20
err0
PREAI
errJennifer Keating Litton; Johannes Ettl; Sara A. Hurvitz; Miguel Martin; Henri Roche; Kyung-Hun Lee; Annabel Goodwin; Tiziana Usari; Silvana Lanzalone; Carolin Guenzel; Joanne Lorraine Blum; Hope S. Rugo
err分享
err收藏
Modulating Enzyme Activity using Engineered Nanomaterials利用工程纳米材料调控酶活性
err2024-09-25
err0
PREAI
errAtri Bhattacharya; Subrata Pandit; Seungheon Lee; Sasha B. Ebrahimi; Devleena Samanta
err分享
err收藏
学者 查看更多内容